Eltrombopag Anabiosis

What Is Eltrombopag Anabiosis and What Is It Used For?

Eltrombopag Anabiosis is a thrombopoietin receptor agonist (TPO-RA) prescribed for the treatment of low platelet counts (thrombocytopenia). It stimulates the bone marrow to produce more platelets and is used in chronic immune thrombocytopenia (ITP), severe aplastic anemia, and hepatitis C-associated thrombocytopenia.

Eltrombopag belongs to a class of medications known as thrombopoietin receptor agonists. Thrombopoietin (TPO) is a natural hormone produced primarily by the liver that plays a central role in regulating platelet production. Platelets are small blood cell fragments essential for blood clotting and wound healing. When platelet counts drop too low (a condition called thrombocytopenia), the risk of abnormal bleeding increases significantly.

Unlike recombinant thrombopoietin, eltrombopag is a small-molecule, non-peptide agonist that binds to the transmembrane domain of the TPO receptor (c-Mpl) rather than its extracellular domain. This unique binding site means eltrombopag acts additively with endogenous TPO, triggering intracellular signaling cascades including the JAK/STAT and MAPK pathways. These signals stimulate the proliferation and differentiation of megakaryocytes, the large bone marrow cells from which platelets are derived.

The medication is approved for several specific indications in adults and, in some cases, children aged 1 year and older. The primary approved uses include treatment of chronic immune thrombocytopenia (ITP) in patients who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. ITP is an autoimmune condition in which the body's immune system mistakenly attacks and destroys its own platelets, leading to dangerously low platelet counts.

Additionally, eltrombopag has received regulatory approval for the treatment of thrombocytopenia in patients with chronic hepatitis C virus (HCV) infection, where low platelet counts may prevent the initiation or continuation of interferon-based antiviral therapy. It is also approved as part of combination immunosuppressive therapy for severe aplastic anemia (SAA) in patients who have had an inadequate response to initial immunosuppressive treatment.

How does Eltrombopag Anabiosis work in the body?

After oral administration, eltrombopag is absorbed from the gastrointestinal tract with peak plasma concentrations typically reached within 2 to 6 hours. The bioavailability of eltrombopag is approximately 52%. It is highly protein-bound (greater than 99%) in plasma and is primarily metabolized by the liver through oxidation via cytochrome P450 enzymes CYP1A2 and CYP2C8, as well as glucuronidation by UGT1A1 and UGT1A3.

The terminal elimination half-life of eltrombopag ranges from approximately 21 to 32 hours, supporting once-daily dosing. Excretion occurs predominantly via feces (approximately 59%) and to a lesser extent via urine (approximately 31%). Notably, eltrombopag chelates polyvalent cations such as calcium, iron, magnesium, aluminium, selenium, and zinc, which significantly reduces its absorption when taken with foods or supplements containing these minerals.

What Should You Know Before Taking Eltrombopag Anabiosis?

Before starting eltrombopag, your doctor must assess your liver function, platelet count, and peripheral blood smear. The medication is contraindicated in patients with severe hepatic impairment and requires dose adjustments in patients of East Asian descent or those with hepatic impairment.

Contraindications

Eltrombopag Anabiosis should not be used in patients with a known hypersensitivity to eltrombopag or any of the excipients in the formulation. It is also contraindicated in patients with severe hepatic impairment (Child-Pugh score of 10 or greater), as the liver is primarily responsible for metabolizing the drug and impaired hepatic function can lead to dangerously elevated drug levels.

Patients with pre-existing risk factors for thromboembolic events should be carefully evaluated before starting treatment, as eltrombopag may increase the risk of blood clot formation, particularly when platelet counts exceed therapeutic targets. A thorough assessment of the patient's medical history, including any prior history of deep vein thrombosis, pulmonary embolism, stroke, or myocardial infarction, is essential before initiating therapy.

Warnings and Precautions

Hepatotoxicity is one of the most significant risks associated with eltrombopag therapy. Elevated liver enzymes (ALT and AST), as well as increases in bilirubin levels, have been reported in clinical trials. Liver function tests should be performed before initiation, every two weeks during the dose adjustment phase, and monthly once a stable dose has been established. If ALT levels rise to three times the upper limit of normal or higher and are progressive, persistent for four weeks or more, accompanied by elevated direct bilirubin, or accompanied by clinical symptoms of liver injury, treatment should be discontinued.

There is also a concern regarding bone marrow reticulin fiber formation. Eltrombopag, by stimulating the TPO receptor, may increase the risk of reticulin fiber deposition in the bone marrow. Before initiating treatment, a peripheral blood smear should be examined to establish a baseline level of cellular morphological abnormalities. If new or worsening morphological abnormalities (such as teardrop cells, nucleated red blood cells, or immature white blood cells) are observed, eltrombopag should be discontinued and a bone marrow biopsy considered.

Rebound thrombocytopenia is another important consideration. Upon discontinuation of eltrombopag, platelet counts may fall to levels below those present before treatment initiation. This rebound effect typically occurs within two weeks of stopping treatment and can increase the risk of bleeding. Patients should be monitored closely for at least four weeks after discontinuation, with regular complete blood count assessments.

Pregnancy and Breastfeeding

Eltrombopag should not be used during pregnancy unless the potential benefit to the mother clearly outweighs the potential risk to the fetus. Animal reproduction studies have demonstrated adverse effects on embryo-fetal development, including reduced fetal body weights and increased pre- and post-implantation losses at exposures that were clinically relevant. Women of childbearing potential should be advised to use effective contraception during treatment.

It is not known whether eltrombopag is excreted in human breast milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue breastfeeding or to discontinue the drug, taking into account the importance of the drug to the mother.

Special Populations

Patients of East Asian descent (including Chinese, Japanese, Korean, and Taiwanese patients) may have higher eltrombopag exposures due to pharmacogenomic differences. A reduced starting dose of 25 mg once daily (rather than the standard 50 mg) is recommended for these patients. Dose adjustments should also be made in patients with hepatic impairment, with lower starting doses recommended for those with mild to moderate hepatic dysfunction.

In pediatric patients aged 1 year and older with chronic ITP, eltrombopag has been studied and approved, with age- and weight-appropriate dosing guidelines. The safety and efficacy in children under 1 year of age have not been established. Elderly patients do not require specific dose adjustments based solely on age, though comorbidities and concomitant medications should be carefully considered.

How Does Eltrombopag Anabiosis Interact with Other Drugs?

Eltrombopag has clinically significant interactions with several medications and supplements. It is a potent inhibitor of OATP1B1 and BCRP transporters, significantly increasing rosuvastatin exposure. Polyvalent cation-containing products (antacids, calcium, iron) drastically reduce eltrombopag absorption and must be separated by at least 4 hours.

Drug interactions with eltrombopag occur through several distinct mechanisms. As a chelating agent for polyvalent cations, eltrombopag forms insoluble complexes with minerals such as calcium, iron, magnesium, aluminium, and zinc, which dramatically reduce its oral bioavailability. Additionally, eltrombopag is an inhibitor of several drug transporters, including organic anion transporting polypeptide 1B1 (OATP1B1), breast cancer resistance protein (BCRP), and organic anion transporter 3 (OAT3).

From a metabolic perspective, eltrombopag is primarily metabolized by CYP1A2 and CYP2C8, with additional contribution from UGT1A1 and UGT1A3 glucuronidation. Medications that induce or inhibit these enzymes can potentially alter eltrombopag exposure, though clinically meaningful interactions through CYP-mediated pathways appear to be less frequent than transporter-based interactions.

Major Interactions

The interaction between eltrombopag and rosuvastatin is considered one of the most clinically significant. In pharmacokinetic studies, co-administration resulted in a 103% increase in rosuvastatin peak plasma concentration (Cmax) and a 55% increase in total exposure (AUC). This increase is attributed to eltrombopag's inhibition of the OATP1B1 and BCRP transporters, which are critical for the hepatic uptake and distribution of rosuvastatin. Patients receiving both medications should be monitored closely for signs and symptoms of statin-related myopathy and rhabdomyolysis, and rosuvastatin dose reduction should be considered.

The chelation interaction with polyvalent cation-containing products is also of major clinical significance. Co-administration with aluminium- and magnesium-containing antacids reduces the AUC of eltrombopag by approximately 70%, which can render the medication clinically ineffective. This interaction extends to all polyvalent cation-containing products, including calcium supplements, iron preparations, and mineral-fortified foods.

Minor Interactions

Eltrombopag is metabolized in part by CYP1A2. While potent CYP1A2 inhibitors (such as fluvoxamine and ciprofloxacin) may theoretically increase eltrombopag levels, and CYP1A2 inducers (such as tobacco smoking and omeprazole) may decrease them, these interactions are generally considered less clinically significant than the transporter-based interactions. Nevertheless, patients starting or stopping CYP1A2 modulators during eltrombopag therapy should have their platelet counts monitored more frequently.

What Is the Correct Dosage of Eltrombopag Anabiosis?

The initial dose for most adults with chronic ITP is 50 mg once daily, taken on an empty stomach. Patients of East Asian descent should start at 25 mg daily. Dose adjustments are made based on platelet count response, with a maximum dose of 75 mg daily. The goal is the lowest dose that maintains a platelet count sufficient to reduce the risk of bleeding.

Dosing of eltrombopag is highly individualized and based on the specific indication, patient population, platelet count response, and tolerability. Regular platelet count monitoring is essential throughout treatment to guide dose adjustments. The overarching principle of eltrombopag dosing is to use the lowest dose that achieves and maintains a platelet count of at least 50,000/mcL (50 x 10⁹/L) as needed to reduce the risk of bleeding.

Adults

For adults with chronic ITP, the recommended starting dose is 50 mg once daily. The dose should be adjusted to achieve and maintain a platelet count of at least 50 x 10⁹/L. Dose increases should occur in increments of 25 mg at intervals of no less than 2 weeks, up to a maximum dose of 75 mg daily. If the platelet count does not increase to a level sufficient to avoid clinically important bleeding after 4 weeks at the maximum dose of 75 mg daily, treatment should be discontinued.

Conversely, if the platelet count exceeds 200 x 10⁹/L, the dose should be decreased by 25 mg. If the platelet count exceeds 400 x 10⁹/L, eltrombopag should be temporarily withheld and platelet counts monitored twice weekly. Once the platelet count falls below 150 x 10⁹/L, treatment may be reinitiated at a dose reduced by 25 mg.

Children

In pediatric patients aged 1 to 5 years with chronic ITP, the recommended starting dose is 25 mg once daily. For children aged 6 to 17 years, the starting dose mirrors the adult recommendation of 50 mg once daily, with the exception of patients of East Asian descent, who should start at 25 mg daily. The same dose adjustment principles used in adults apply to pediatric patients, with the same maximum dose of 75 mg daily.

Elderly

No specific dose adjustment is required solely on the basis of age. However, elderly patients frequently have comorbid conditions and receive concomitant medications that may influence eltrombopag pharmacokinetics or increase the risk of adverse effects. Hepatic and renal function should be assessed, and the potential for drug interactions carefully evaluated. A more conservative approach to dose titration may be appropriate in some elderly patients.

Missed Dose

If a dose of eltrombopag is missed, the patient should take the next dose at the regularly scheduled time. A double dose should not be taken to make up for a missed dose. If doses are frequently missed, patients should be counseled on the importance of adherence to maintain stable platelet counts, as inconsistent dosing can lead to fluctuations in platelet levels and an increased risk of bleeding or thrombosis.

Overdose

In clinical studies, one patient took eltrombopag in a dose of 5,000 mg. The reported adverse effects included mild rash, transient bradycardia, and elevations in liver enzymes and platelet count. There is no specific antidote for eltrombopag overdose. In the event of an overdose, standard supportive measures should be initiated. Platelet counts should be monitored closely, as excessive platelet production may increase the risk of thromboembolic events. Eltrombopag is not expected to be dialyzable due to its high protein binding (>99%).

What Are the Side Effects of Eltrombopag Anabiosis?

The most common side effects of eltrombopag include nausea, diarrhea, and elevated liver enzymes. Serious adverse effects include hepatotoxicity, thromboembolic events, and bone marrow reticulin formation. The side effect profile varies by indication and may be influenced by concomitant therapies.

Like all medications, eltrombopag can cause side effects, although not everybody experiences them. The frequency and severity of adverse effects vary depending on the indication for which the drug is prescribed, the dose used, and individual patient factors. In clinical trials, the most frequently reported adverse reactions were generally mild to moderate in severity.

It is important to distinguish between adverse effects directly attributable to eltrombopag and those related to the underlying condition being treated. For example, patients with chronic hepatitis C receiving eltrombopag alongside antiviral therapy may experience a different side effect profile compared to patients with ITP receiving eltrombopag as monotherapy.

Hepatotoxicity deserves special attention as it is one of the most clinically significant adverse effects. In clinical trials for ITP, ALT elevations to three or more times the upper limit of normal were observed in approximately 10% of eltrombopag-treated patients compared to 3% of placebo-treated patients. Most cases were asymptomatic and reversible upon dose reduction or discontinuation. However, rare cases of severe drug-induced liver injury with jaundice have been reported, emphasizing the critical importance of regular liver function monitoring.

Thromboembolic events represent another area of serious concern. In clinical trials, thromboembolic events were reported in approximately 3-6% of eltrombopag-treated patients, compared to 2-4% of placebo-treated patients. These events include deep vein thrombosis, pulmonary embolism, portal vein thrombosis (particularly in patients with chronic liver disease), and arterial events such as myocardial infarction and stroke. The risk appears to be related to the degree of platelet count elevation and is greatest when platelet counts exceed 200 x 10⁹/L.

How Should You Store Eltrombopag Anabiosis?

Store Eltrombopag Anabiosis tablets at room temperature (below 30°C / 86°F) in the original packaging to protect from moisture. Keep out of reach of children. Do not use after the expiry date printed on the packaging.

Proper storage of eltrombopag is important to maintain the stability and efficacy of the medication. The tablets should be stored at room temperature, not exceeding 30°C (86°F). They should be kept in the original blister packaging or bottle to protect them from moisture and light. The medication should not be stored in the bathroom or near a sink, where humidity levels tend to be higher.

As with all medications, eltrombopag should be kept out of the sight and reach of children. The packaging should be checked regularly, and any tablets that appear discolored, damaged, or have passed their expiry date should not be used. Unused or expired medication should be returned to a pharmacy for proper disposal in accordance with local regulations. Do not dispose of medications in household waste or wastewater.

When traveling with eltrombopag, patients should keep the medication in its original packaging and transport it in carry-on luggage rather than checked baggage to avoid exposure to extreme temperatures. A letter from the prescribing physician may be useful for international travel, as the medication is a prescription-only product.

What Does Eltrombopag Anabiosis Contain?

Each Eltrombopag Anabiosis film-coated tablet contains 25 mg of eltrombopag (as eltrombopag olamine) as the active ingredient. The tablets also contain various inactive ingredients (excipients) that serve as fillers, binders, disintegrants, lubricants, and coating agents.

The active pharmaceutical ingredient in Eltrombopag Anabiosis is eltrombopag olamine (also known as eltrombopag diethanolamine salt). Eltrombopag olamine is a small-molecule, non-peptide thrombopoietin receptor agonist with the molecular formula C₂₅H₂₂N₄O₄ (free acid form). The olamine salt form was selected for pharmaceutical development due to its superior solubility characteristics and stability profile.

The inactive ingredients (excipients) in the film-coated tablets typically include pharmaceutical-grade substances serving specific functions: microcrystalline cellulose and mannitol serve as diluents and fillers; sodium starch glycolate or croscarmellose sodium functions as a disintegrant to facilitate tablet dissolution; povidone or hypromellose acts as a binder; and magnesium stearate is used as a lubricant. The film coating may contain hypromellose, titanium dioxide, polysorbate 80, and iron oxide pigments for tablet identification.

Patients with known allergies to any excipient should carefully review the complete ingredient list provided in the package insert before starting treatment. The tablets do not contain lactose, gluten, or animal-derived ingredients. However, specific formulations may vary by manufacturer, so patients should always check the product-specific information provided with their particular supply.